Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2024 Jun 13.
Published in final edited form as: Angew Chem Int Ed Engl. 2021 Sep 2;60(41):22270–22275. doi: 10.1002/anie.202109082

Forrestiacids A and B, Pentaterpene Inhibitors of ACL and Lipogenesis: Extending the Limits of Computational NMR Methods in the Structure Assignment of Complex Natural Products

Juan Xiong 1, Peng-Jun Zhou 2, Hao-Wen Jiang 3, Ting Huang 4, Yu-Hang He 5, Ze-Yu Zhao 6, Yi Zang 7, Yeun-Mun Choo 8, Xiaojuan Wang 9, Amar G Chittiboyina 10, Pankaj Pandey 11, Mark T Hamann 12, Jia Li 13, Jin-Feng Hu 14,15
PMCID: PMC11173361  NIHMSID: NIHMS1992038  PMID: 34374477

Abstract

Forrestiacids A (1) and B (2) are a novel class of [4+2] type pentaterpenoids derived from a rearranged lanostane moiety (dienophile) and an abietane unit (diene). These unprecedented molecules were isolated using guidance by molecular ion networking (MoIN) from Pseudotsuga forrestii, an endangered member of the Asian Douglas Fir Family. The intermolecular hetero-Diels–Alder adducts feature an unusual bicyclo[2.2.2]octene ring system. Their structures were elucidated by spectroscopic analysis, GIAO NMR calculations and DP4 + probability analyses, electronic circular dichroism calculations, and X-ray diffraction analysis. This unique addition to the pentaterpene family represents the largest and the most complex molecule successfully assigned using computational approaches to predict accurately chemical shift values. Compounds 1 and 2 exhibited potent inhibitory activities (IC50s < 5 μM) of ATP-citrate lyase (ACL), a new drug target for the treatment of glycolipid metabolic disorders including hyperlipidemia. Validating this activity 1 effectively attenuated the de novo lipogenesis in HepG2 cells. These findings provide a new chemical class for developing potential therapeutic agents for ACL-related diseases with strong links to traditional medicines.

Keywords: forrestiacids, lipogenesis inhibitors, natural products, structure elucidation, terpenoids


The elevated level of low-density lipoprotein cholesterol (LDL-C) represents a key risk factor for atherosclerotic cardiovascular disease (CVD), which is associated with high morbidity and mortality as well as increasing health-care costs.[1] Statins are effective at decreasing LDL-C and CVD, but are associated with some muscle- and skeletal-related side-effects.[2] The adenosine triphosphate (ATP)-citrate lyase (ACL) is an important enzyme linking carbohydrate to lipid metabolism by converting citrate to acetyl-CoA, which serves as a common substrate for fatty acid and cholesterol biosynthesis.[3] ACL has been recently identified as a novel drug target for hyperlipidemia, hypercholesterolemia and other metabolic disorders.[4,5] ACL inhibitors may suppress the synthesis of fatty acids and cholesterol, and significantly lower the elevated level of LDL-C. An excellent example is the recently approved dicarboxylic acid derivative, bempedoic acid, which is now prescribed for use in statin resistant hypercholesterolemia.[5]

There is still considerable effort required to identify improved ACL inhibitors as bempedoic acid has some treatment-limiting side-effects. The plant family Pinaceae is ranked among the top-20 privileged drug-prolific families that produce a high number of approved drugs.[6] Natural products (NPs) from Pinaceae species have been used extensively in both traditional Asian and Native American medicines involving metabolic diseases making them ideal candidates for the discovery of ACL inhibitors.[6,7] Continuing our research towards the identification of new bioactive NPs from endangered conifers,[8] Pseudotsuga forrestii Craib, a relict and vulnerable Pinaceae species,[7,9] was phytochemically investigated.[10] In this study, by the implementation of HRMS/MS-based molecular ion networking (MoIN),[11] a pair of unique [4+2]-adducts [i.e., forrestiacids A (1) and B (2), Figure 1] featuring an unprecedented pentaterpene carbon skeleton formed by intermolecular Diels–Alder cycloaddition between a rearranged 6/6/5/5-fused lanostane unit and an abietadiene unit, were obtained from the twigs/needles of P. forrestii. Herein, their isolation, structural characterization, biogenetic consideration, and inhibitory effects against ACL and lipogenesis are presented.

Figure 1.

Figure 1.

A new class of pentaterpenes from Pseudotsuga forrestii (The bonds in red showing the connective sites between the tri- and di-terpenoid units).

Isolation of the novel chemical class of [4+2]-adducts was facilitated under the guidance of HPLC-HRMS/MS (positive mode)-based MoIN as enabled through the Cytoscape platform (https://cytoscape.org/).[11] This analysis revealed two unique signals at m/z 769 with different retention times (Figure 2). Subsequently, target purification of these m/z 769 metabolites afforded the terpenoid [4+2] hetero-dimers 1 and 2.

Figure 2.

Figure 2.

MoIN of the mentioned MeOH extract of P. forrestii. left: Organized landscape of complete network; right: the MoIN cluster with signals at m/z 769.

Forrestiacid A (1), colorless crystals from MeOH, possesses the molecular formula C50H72O6 as assigned by the HRESIMS ion at m/z 769.5392 [M + H]+ (calcd 769.5402) and 13C NMR data (Table S1). In the upfield region of its 1H NMR spectrum, seven singlet methyls resonating at δH 0.62 (s, H3-20′), 0.78 (s, H3-18), 1.09 (s, H3-28/H3-29), 1.11 (s, H3-19), 1.16 (s, H3-19′), 1.18 (s, H3-26), and three doublet methyls at 0.74 (d, J = 6.5 Hz, H3-21), and 1.04 (d, J = 6.5 Hz, H3-15′ and H3-16′) were observed (Table S2). In the down-field region, three olefinic protons were recognized, with two [δH 4.72, 4.46 (each br s)] ascribed to an exocyclic methylene group and the rest (δH 5.36, br s) for a trisubstituted double bond. The 13C NMR data of 1 (Table S1), with the aid of DEPT and HSQC NMR experiments, exhibited 50 carbon resonances comprising two ketocarbonyls (δC 216.7 and 213.8), two carboxyls (δC 186.6 and 184.2), six olefinic carbons, eight sp3 quaternary carbons, seven sp3 methines, 15 sp3 methylenes, and 10 methyls. In combination with the number of the methyls and methyl-derived groups (i.e., exocyclic methylenes and carboxyls), the observation of 50 carbon signals and 15 indices of hydrogen deficiency indicated that compound 1 is a hetero-dimer of a C30-triterpenoid moiety fused with a C20-diterpenoid unit.

For the triterpenoid part, a close comparison of the NMR data of 1 with the co-occurring neoabiestrine F,[12] a rearranged lanostane with an intriguing spiro[4,4]nonane ring, permitted the presence of a similar spiro-lanostane segment in the structure of 1. More details came from the interpretation of its 2D NMR data. The presence of two discontinuous spin systems of CH2(15)-CH2(16) and CH3(21)-CH(20)-CH2-(22) as evidenced from the 1H-1H COSY correlations, and the HMBC correlations from H3-18 to the spiro-carbon (C-13) and C-16/C-17/C-20, from H2-30 to C-13/C-14/C-15, and from H3-19 to C-9, confirmed the assignment of an 8(14→13)-abeo-17,13-friedo-lanost-8,14(30)-diene[13] fragment for 1 (Figure 3 a). Consistent with this, the observed quaternary carbon signal at δC 67.9 was typical for a double allyl nodal carbon atom (C-13) in this class of rearranged 6/6/5/5-fused lanostanes.[13] The carbonyl at δC 216.7 was assigned to C-3 based on its HMBC correlations with the geminal methyls H3-28 and H3-29 as a keto group, whereas the correlations from H2-22 and H-24 to a carbonyl at δC 213.8 allowed it to be positioned at C-23 as an additional keto group. The HMBC spectrum of 1 exhibited correlations from H3-26 to C-24, C-25, and a carboxyl at δC 184.2, indicating C-27 to be carboxylated.

Figure 3.

Figure 3.

2D NMR correlations of forrestiacid A (1).

The remaining 20 carbon resonances comprising a carboxyl, four methyls, six methylenes, five methines, and four quaternary carbons, constructed a diterpenoid unit. The presence of an isopropyl group [δH 1.04 (6 H, d, J = 6.5 Hz), H3-16′/H3-17′; 2.34 (m), H-15′], which in conjunction with the HMBC correlations from H-14′ to C-7′/C-12′, from H3-16′(17′) to C-13′/C-15′, from H3-19′ to C-3′/C-4′/C-5′/C-18′, and from H3-20′ to C-1′/C-5′/C-9′/C-10′ (Figure 3 a), further depicted this diterpenoid unit featuring an abieta-13-ene skeleton. The carboxyl group at δC 186.6 was attached to C-4′ based on its HMBC correlation with H3-19′.

Overall, the triterpene unit was fused with the diterpene via two newly generated C—C bonds of C-25-C-8′ and C-24-C-12′ to form an additional cyclohexene ring (Figure 3 a). This was evidenced by the HMBC correlations of H3-26/C-8′, H-24/C-13′, H-12′/C-24, and H-14′/C-25. The planar structure of 1 was thus delineated. Its relative configuration was established by analyses of proton-proton coupling constants (Table S2) and the ROESY spectrum. The ROE correlations (Figure 3 b) of H3-19/H-2β, H-2β/H3-29, H3-28/H-5, H-5/H-7α, H-7β/H3-18, and H-30b/H-7α ascertained the relative configuration of the triterpenoid moiety to be consistent with those of neoabiestrine F and analogs.[12] Meanwhile, the ROE correlation between H3-19′ and H3-20′, and those between the axial protons of H-5′ (δH 1.69, br d, J = 12.0 Hz) with H-1′α and of H-1′α with H-9′ established the relative configuration of the A/B rings in the diterpenoid moiety as those of usual abietanes[14] (Figure 3 b). The ring C in the diterpenoid portion was fused with the newly formed cyclohexene to form a rigid bicyclo-[2.2.2]octene core and its stereochemistry was determined as shown in Figure 3 b. Analysis of the proton-proton coupling constants revealed that H-24 (br s) and H-12′ (br s) were both equatorially oriented due to their small J values. The strong ROE correlation of H-14′ with H3-20′ positioned the bridge fragment (C-13′ to C-17′) on the β-side of this molecule. H-24 was concluded to adopt the β-orientation from its ROE correlations with H-14′ and H3-16′(17′), whereas Me-26 α-configured owing to the ROE correlation of H3-26/H-9′. The gross structure of 1 was then elucidated as depicted in Figure 1.

Forrestiacid B (2) has the same molecular formula (C50H72O6) as 1 according to the protonated ion at m/z 769.5406 in its HRESIMS. Its 1H and 13C NMR data (Tables S1 and S2) closely resembled those of 1, with noticeable differences occurring at CH-24 (δ 3.35/59.0 in 2 vs. δ 2.79/62.2 in 1), C-25 (δC 55.8 in 2 vs. δC 49.8 in 1), and their neighboring groups. Further interpretation of the HMBC spectrum of 2 revealed its planar structure to be the same as 1, implying that the stereogenic centers C-24 and C-25 in the [4+2]-cyclohexene ring of 2 would adopt different configurations. This inference was confirmed by the ROESY experiment, in which the cross-peaks of H3-20′/H-14′, H-14′/H3-26′, and H-24/H-9′ demonstrated the β-orientation for Me-26 but an α-orientation for H-24 (Figure S2).

To further consolidate the relative configuration assignments for C-24 and C-25 of the above diastereomers 1 and 2, GIAO (the Gauge Independent Atomic Orbital method) 1H and 13C NMR chemical shift (CS) calculations using the corrected mean absolute error (CMAE) and DP4 + probability analyses were performed (for details, see Table S6S14 in the Supporting Information).[15] The results obtained through DP4 + probability analysis predicted (24S,25R)-1 to match well with the experimental data of 1 with 100 % probability [DP4 + (all (H and C) data) and scaled DP4 + (all (H and C) data)] (Table 1 and Table S13). Similarly, (24R,25S)-2 matches closely with the experimental data of 2 with 100 % probability [DP4 + (H and C data)] (Table 1 and Table S14). In addition, for scaled CS values (Table S9S12), the carbon- and proton-CMAE analysis of (24S,25R)-1 and (24R,25S)-2 (Table 1) showed better agreement with the DP4 + study. Overall, the CMAE and DP4 + probability analyses verified the relative configurations of compounds 1 and 2 to be (5R*,10S*,13R*,17S*,20R*,24S*,25R*,4′R*,−5′R*,8′S*,9′R*,10′R*,12′R*) and (5R*,10S*,13R*,17S*,20R*,−24R*,25S*,4′R*,5′R*,8′S*,9′R*,10′R*,12′R*), respectively.

Table 1:

Mean absolute error (MAE), corrected MAE, and DP4 + probability analyses (sarottinmr.weebly.com) for (24S,25R)-1 and (24R,25S)-2. The PCM/mPW1PW91/6–311 + G(d,p) level of theory was used for the analysis.

1 2 Units
calc. (24S,25R)-1 calc. (24R,25S)-2 calc. (24S,25R)-1 calc. (24R,25S)-2

All DP4 + data 100.00 0.00 0.00 100.00 %
 MAE (carbon) 4.93 5.32 4.90 5.02 ppm
 MAE (proton) 0.20 0.28 0.22 0.23 ppm
CMAE (carbon) 1.86 2.56 2.17 1.96 ppm
CMAE (proton) 0.17 0.22 0.18 0.17 ppm

The reliability of the absolute configuration assignments was then corroborated by the electronic circular dichroism (ECD) calculation using time-dependent density functional theory (TDDFT).[16] In the ECD curve of 1, a positive Cotton effect (CE) at 222 nm was observed (Δε + 13.35), in contrast to a negative one for 2ε−27.16, 227 nm) (Figure S3). Such a CE around 220 nm is aroused by the electronic transitions involving the electrons of the carbonyl at C-23 and the Δ13′(14′)-olefinic bond.[17] As shown in Figure S3, the respective similarities between the experimental and computed ECD spectra of 1 and 2 allowed the determination of (5R,10S,13R,17S,20R,24S,25R,4′R,5′R,8′S,9′R,10′R,12′R)−1 and (5R,10S,13R,17S,20R,24R,25S,4′R,5′R,8′S,9′R,10′R,−12′R)-2. Finally, the above assignments (including both relative and absolute configurations) were unambiguously confirmed by a single-crystal X-ray crystallography study of 1 with Ga Kα radiation [absolute structure parameter 0.17-(11)] (Figure 4).[18]

Figure 4.

Figure 4.

ORTEP representation of forrestiacid A (1).

Considering that neoabiestrine F (Scheme 1),[12] a rearranged lanostane with an intriguing spiro[4,4]nonane moiety to be the precursor for the isolates, and several abietenes (e.g., dehydroabietic acid[14]) were found co-occurred in the title plant, it is reasonable to propose that the hetero-dimers would be formed by an intermolecular [4+2] Diels–Alder (DA) cycloaddition between the triterpene and diterpene units. The diterpenoid levopimaric acid[19] would act as the ‘diene’ in the DA reaction. Meanwhile, neoabiestrine F, a rearranged lanostane bearing an 23-oxo-24(E)-enoic acid fragment could serve as the electron-deficient ‘dienophile’. The triterpenoid and diterpenoid units were connected via the newly formed C-25-C-8′ and C-24-C-12′ bonds. Interestingly, in this study, 1 and 2 were isolated as a pair of natural isomers derived from exo-/endo-selectivities in [4+2] dimerization, but with the endo-cycloadducts (1) as the favored one (isolated amount 1.2 g for 1 and only 0.1 g for 2). Besides, the [4+2] adducts 1 and 2 derived from the E-configured dienophile adopt the cis ring fusion mode (i.e., 27-COOH and H-24 being cofacial), as illustrated.

Scheme 1.

Scheme 1.

Proposed biosynthetic pathway for forrestiacids A (1) and B (2).

The DA reaction has been an extremely valuable synthetic method for the construction of unsaturated six-membered rings.[20] A number of naturally occurring terpenoid [4+2]-adducts have been reported, and have attracted attention due to their complex architectures, bioactivities, and synthetic challenges.[21] Among them, most are terpenoid homo-dimers, whereas the hetero-dimers are quite rare.[2123] As for the triterpene-diterpene [4+2] adducts, only three examples have been encountered so far: two cycloartane-labdane adducts from Pseudolarix amabilis (Pinaceae)[24] and a lupane-abietane adduct from two Hippocratea species (Celastraceae).[25] Forrestiacids represent a novel chemical class of [4+2] hetero-dimers formed between a lanostane-derived triterpene and an abietane-type diterpene.

Biosynthesis of natural [4+2]-adducts occurs via either non-catalytic spontaneous dimerization or enzyme-catalytic reaction. In the present study, spontaneous reactions between neoabiestrine F and levopimaric acid either at room temperature for a period of 6-month or under refluxing in toluene overnight were performed, but no expected adduct could be detected by TLC and HPLC analysis (details, please refer to the experimental section in the Supporting Information). Natural Diels–Alderases[26] might be responsible for their biosynthesis, which warrants future exploration.

The two terpenoid [4+2]-adducts were evaluated in ACL assays to assess their activity.[14] The known ACL inhibitor BMS 303141[27] was used as the positive control. As illustrated in Table 2, forrestiacids A (1) and B (2) displayed significant inhibition against ACL, with IC50 values of 4.12 and 3.57 μM, respectively. In contrast, the two possible precursors, neoabiestrine F and levopimaric acid, were inactive (IC50s > 20 μM). Hence, the existence of the bicyclo[2.2.2]octene core is crucial for the ACL inhibitory activity of the hetero-dimers. As evidenced by the data, the stereoisomers (endo- or exo-type) showed comparable effects. ACL inhibitors may suppress the synthesis of fatty acids and cholesterol, and significantly lower the elevated level of LDL-C.[5] Interestingly, forrestiacids and bempedoic acid[5] all are dicarboxylic acid derivatives.

Table 2:

ACL inhibitory effects of compounds 1 and 2.

Compounds IC50 (μM)[a]

1 4.12±0.62
2 3.57±0.39
BMS 303141[27] 0.46±0.13
[a]

These data are expressed as the mean ± SEM of triplicate experiments.

The major component, forrestiacid A (1, yield 0.008 %), was then subjected to a de novo lipogenesis assay (Figure 5). It elicited dual inhibition on [14C]-labeled acetate incorporation into fatty acid and cholesterol in HepG2 cells, in a concentration-dependent manner. Remarkably, the treatment of compound 1 resulted in dramatic reductions in fatty acid (≈75 %, P < 0.05), and cholesterol (≈93 %, P < 0.05) syntheses at all test concentrations (10, 20, and 40 μM). The positive control, 1 mM metformin caused a dual decrease in fatty acid and cholesterol, only by 33.59 and 30.04 %, respectively. Due to the modest activity against ACL shown in Table 2 relative to the highly significant activity in lipogenesis shown in Figure 5, a docking study with ACL and four other protein targets laying key roles in lipogenesis (i.e., ACC, FAS, SCD1, and PPAR-α, for details see SI) revealed a potential synergistic interaction with two or more of these targets leading to the potent inhibition of lipogenesis. This further elevates the potential value of these molecules as therapeutic agents in the control of lipogenesis.

Figure 5.

Figure 5.

Effects of compound 1 on de novo lipogenesis in HepG2 cells. Detection of syntheses of fatty acid (A) and cholesterol (B) in HepG2 after treated with 1 for 20 h and incubated with 14C labeled acetate for another 4 h. n = 3 for all groups. * P < 0.05 compared with DMSO group. All error bars, s.e.m.

In summary, two new pentaterpenoids [4+2] hetero-dimers were isolated and characterized from the vulnerable conifer P. forrestii, under the guidance of MS/MS-based MoIN. The intriguing pentaterpene-like skeleton comprises a rearranged 6/6/5/5-fused lanostane-type triterpene unit conjugated with an abietane-type diterpene unit by an intermolecular Diels–Alder cycloaddition. The applications of quantum NMR calculations with the aid of DP4 + probability analysis provide ideal complementary tools to facilitate the elucidation process in some challenging cases.[28] Forrestiacids represent one of the largest terpenoid molecules published to date,[28] and expand the utility of computational chemical shift NMR approaches as effective and powerful strategies for assign and verify the correct NMR structure. Both exhibited potent inhibitory activities against ACL (IC50s < 5 mM). Forrestiacid A (1) is shown to significantly inhibit the de novo fatty acid and cholesterol synthesis in HepG2 cells. These unique naturally occurring lipogenesis inhibitors reveal the importance of protecting endangered plants and interrogating traditional Asian and Native American medicines as potential sources of new and complex NP therapeutics.

Supplementary Material

ForrestiacidsSI

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (Nos. 21937002, 81773599, 21772025). Thanks to the Mississippi Center for Supercomputing Research.

Footnotes

Conflict of Interest

The authors declare no conflict of interest.

Contributor Information

Juan Xiong, School of Pharmacy, Fudan University, Shanghai 201203 (P. R. China).

Peng-Jun Zhou, School of Pharmacy, Fudan University, Shanghai 201203 (P. R. China).

Hao-Wen Jiang, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203 (P. R. China).

Ting Huang, School of Pharmacy, Fudan University, Shanghai 201203 (P. R. China).

Yu-Hang He, School of Pharmacy, Fudan University, Shanghai 201203 (P. R. China).

Ze-Yu Zhao, School of Pharmacy, Fudan University, Shanghai 201203 (P. R. China).

Yi Zang, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203 (P. R. China).

Yeun-Mun Choo, Chemistry Department, Faculty of Science, University of Malaya Kuala Lumpur 50603 (Malaysia).

Xiaojuan Wang, School of Pharmacy, Lanzhou University, Lanzhou 730000, Gansu (P. R. China).

Amar G. Chittiboyina, National Center for Natural Products Research, University of Mississippi, Oxford, MS 38677 (USA)

Pankaj Pandey, National Center for Natural Products Research, University of Mississippi, Oxford, MS 38677 (USA).

Mark T. Hamann, Colleges of Pharmacy and Medicine, Medical University of South Carolina, Charleston, SC 29425-5700 (USA)

Jia Li, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203 (P. R. China).

Jin-Feng Hu, School of Pharmacy, Fudan University, Shanghai 201203 (P. R. China); School of Advanced Study, Taizhou University, Taizhou 318000, Zhejiang (P. R. China).

References

  • [1].https://www.heart.org/en/health-topics/consumer-healthcare/what-iscardiovascular-disease.
  • [2].Adhyaru BB, Jacobson TA, Nat. Rev. Cardiol. 2018, 15, 757 – 769. [DOI] [PubMed] [Google Scholar]
  • [3].a) Verschueren KHG, Blanchet C, Felix J, Dansercoer A, De Vos D, Bloch Y, Van Beeumen J, Svergun D, Gutsche I, Savvides SN, Verstraete K, Nature 2019, 568, 571 – 575; [DOI] [PubMed] [Google Scholar]; b) Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB, Science 2009, 324, 1076 – 1080; [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Wang Q, Jiang L, Wang J, Li S, Yu Y, You J, Zeng R, Gao X, Rui L, Li W, Liu Y, Hepatology 2009, 49, 1166 – 1175. [DOI] [PubMed] [Google Scholar]
  • [4].a) Pinkosky SL, Groot PHE, Lalwani ND, Steinberg GR, Trends Mol. Med. 2017, 23, 1047 – 1063; [DOI] [PubMed] [Google Scholar]; b) Granchi C, Eur. J. Med. Chem. 2018, 157, 1276 – 1291. [DOI] [PubMed] [Google Scholar]
  • [5].a) Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM, Engl N. J. Med. 2019, 380, 1022 – 1032; [DOI] [PubMed] [Google Scholar]; b) Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PHE, Steinberg GR, Lalwani ND, Nat. Commun. 2016, 7, 13457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Zhu F, Qin C, Tao L, Liu X, Shi Z, Ma X, Jia J, Tan Y, Cui C, Lin J, Tan C, Jiang Y, Chen Y, Proc. Natl. Acad. Sci. USA 2011, 108, 12943 – 12948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [7].Fu L-K, Li N, Mill RR, Flora of China (Eds.: Wu Z-Y, Raven PH), Science Press (Beijing) & Missouri Botanical Garden Press; (St. Louis: ), 1999, Vol. 4, pp. 11 – 52. [Google Scholar]
  • [8].Ma G-L, Guo N, Wang X-L, Li J, Jin Z-X, Han Y, Dong S-Z, Xiong J, Hu J-F, Bioorg. Chem. 2020, 105, 104445. [DOI] [PubMed] [Google Scholar]
  • [9].Fu L-K, Jin J-M, China Plant Red Data Book. Rare and Endangered Plants I, Science Press, Beijing and New York, 1992. [Google Scholar]
  • [10].This is Part XX of the “Phytochemical and biological studies on rare and endangered plants endemic to China” series; for Part XIX, see ref.8 herein. [Google Scholar]
  • [11].Zou Y, Wang XJ, Sims J, Wang B, Pandey P, Welsh CL, Stone RP, Avery MA, Doerksen RJ, Ferreira D, Anklin C, Valeriote FA, Kelly M, Hamann MT, J. Am. Chem. Soc. 2019, 141, 4338 – 4344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Li Y-L, Gao Y-X, Yang X-W, Jin H-Z, Ye J, Simmons L, Wang N, Steinmetz A, Zhang W-D, Phytochemistry 2012, 81, 159 – 164. [DOI] [PubMed] [Google Scholar]
  • [13].Raldugin VA, Shakirov MM, Leibyuk TV, Shevtsov SA, Chem. Nat. Compd. 1991, 27, 444 – 449. [Google Scholar]
  • [14].Huang T, Ying S-H, Li J-Y, Chen H-W, Zang Y, Wang W-X, Li J, Xiong J, Hu J-F, Phytochemistry 2020, 169, 112184. [DOI] [PubMed] [Google Scholar]
  • [15].Grimblat N, Zanardi MM, Sarotti AM, J. Org. Chem. 2015, 80, 12526 – 12534. [DOI] [PubMed] [Google Scholar]
  • [16].Bruhn T, Schaumloffel A, Hemberger Y, Bringmann G, Chirality 2013, 25, 243 – 249. [DOI] [PubMed] [Google Scholar]
  • [17].Li Y-L, Zhang S-D, Jin H-Z, Tian J-M, Shen Y-H, Yang X-W, Li H-L, Zhang W-D, Tetrahedron 2012, 68, 7763 – 7767. [Google Scholar]
  • [18].Deposition Number 2058295 contains the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service. [Google Scholar]
  • [19].Oleson KR, Schwartz DT, Phytochem. Rev. 2016, 15, 985 – 1008. [Google Scholar]
  • [20].a) Diels O, Alder K, Liebigs Ann. Chem. 1928, 460, 98 – 122; [Google Scholar]; b) Stocking EM, Williams RM, Angew. Chem. Int. Ed. 2003, 42, 3078 – 3115; [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2003, 115, 3186 – 3223. [Google Scholar]
  • [21].a) Liu B, Fu S, Zhou C, Nat. Prod. Rep. 2020, 37, 1627 – 1660; [DOI] [PubMed] [Google Scholar]; b) Oikawa H, Tokiwano T, Nat. Prod. Rep. 2004, 21, 321 – 352. [DOI] [PubMed] [Google Scholar]
  • [22].Lavoie S, Legault J, Gauthier C, Mshvildadze V, Mercier S, Pichette A, Org. Lett. 2012, 14, 1504 – 1507. [DOI] [PubMed] [Google Scholar]
  • [23].Wei W-J, Song Q-Y, Ying J-C, Li H-Y, Ma K-L, Li Y, Li Y, Gao K, J. Nat. Prod. 2019, 82, 2859 – 2869. [DOI] [PubMed] [Google Scholar]
  • [24].Li B, Kong D-Y, Shen Y-H, Yuan H, Yue R-C, He Y-R, Lu L, Shan L, Li H-L, Ye J, Yang X-W, Su J, Liu R-H, Zhang W-D, Org. Lett. 2012, 14, 5432 – 5435. [DOI] [PubMed] [Google Scholar]
  • [25].Bazzocchi IL, Núñez MJ, Reyes CP, Phytochem. Rev. 2018, 17, 669 – 690. [Google Scholar]
  • [26].Klas K, Tsukamoto S, Sherman DH, Williams RM, J. Org. Chem. 2015, 80, 11672 – 11685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Koerner SK, Hanai J, Bai S, Jernigan FE, OKi M, Komaba C, Shuto E, Sukhatme VP, Sun L, Eur. J. Med. Chem. 2017, 126, 920 – 928. [DOI] [PubMed] [Google Scholar]
  • [28].Marcarino MO, Cicetti S, Zanardi MM, Sarotti AM, Nat. Prod. Rep. 2021, 10.1039/d1np000301. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ForrestiacidsSI

RESOURCES